Open Access

Geniposide protects pulmonary arterial smooth muscle cells from lipopolysaccharide‑induced injury via α7nAchR‑mediated TLR‑4/MyD88 signaling

  • Authors:
    • San-Ying Shen
    • Li-Quan Ren
    • Hui-Dong Chen
    • Hong-Fei Zhu
    • Deng-Feng Zhou
    • Bo Zhang
    • Xiao-Qin Tan
    • Yong-Hua Xie
  • View Affiliations

  • Published online on: August 31, 2021     https://doi.org/10.3892/etm.2021.10668
  • Article Number: 1234
  • Copyright: © Shen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Geniposide is a bioactive iridoid glucoside derived from Gardenia jasminoides that has proven anti‑inflammatory effects against acute lung injury. The aim of this study was to determine whether geniposide could protect pulmonary arterial smooth muscle cells (PASMCs) from lipopolysaccharide (LPS)‑induced injury and to explore the participation of α7 nicotinic acetylcholine receptor (α7nAChR), which was previously reported to suppress pro‑inflammatory cytokine production in LPS‑stimulated macrophages. In the present study, rat PASMCs were isolated and stimulated using LPS. The effect of geniposide on LPS‑induced PASMC injury was then explored. Geniposide exerted anti‑apoptotic and anti‑inflammatory effects on LPS‑treated PASMCs, as demonstrated by the downregulation of pro‑apoptotic proteins and pro‑inflammatory cytokines, respectively. Furthermore, the α7nAChR agonist PNU282987 accentuated the protective effect of geniposide against LPS‑induced injury in PASMCs by inhibiting toll‑like receptor‑4/myeloid differentiation primary response 88 (TLR‑4/MyD88) signaling and downregulating nuclear factor (NF)‑κB expression. Conversely, methyllycaconitine, an inhibitor of α7nAChR, attenuated the effects of geniposide. These findings collectively suggested that in conjunction with geniposide, the activation of α7nAChR may contribute to further mitigating LPS‑induced PASMC apoptosis and inflammation. In addition, the underlying mechanisms critically involve the NF‑κB/MyD88 signaling axis. These results may provide novel insights into the treatment and management of lung diseases via geniposide administration.
View Figures
View References

Related Articles

Journal Cover

November-2021
Volume 22 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shen S, Ren L, Chen H, Zhu H, Zhou D, Zhang B, Tan X and Xie Y: Geniposide protects pulmonary arterial smooth muscle cells from lipopolysaccharide‑induced injury via α7nAchR‑mediated TLR‑4/MyD88 signaling. Exp Ther Med 22: 1234, 2021
APA
Shen, S., Ren, L., Chen, H., Zhu, H., Zhou, D., Zhang, B. ... Xie, Y. (2021). Geniposide protects pulmonary arterial smooth muscle cells from lipopolysaccharide‑induced injury via α7nAchR‑mediated TLR‑4/MyD88 signaling. Experimental and Therapeutic Medicine, 22, 1234. https://doi.org/10.3892/etm.2021.10668
MLA
Shen, S., Ren, L., Chen, H., Zhu, H., Zhou, D., Zhang, B., Tan, X., Xie, Y."Geniposide protects pulmonary arterial smooth muscle cells from lipopolysaccharide‑induced injury via α7nAchR‑mediated TLR‑4/MyD88 signaling". Experimental and Therapeutic Medicine 22.5 (2021): 1234.
Chicago
Shen, S., Ren, L., Chen, H., Zhu, H., Zhou, D., Zhang, B., Tan, X., Xie, Y."Geniposide protects pulmonary arterial smooth muscle cells from lipopolysaccharide‑induced injury via α7nAchR‑mediated TLR‑4/MyD88 signaling". Experimental and Therapeutic Medicine 22, no. 5 (2021): 1234. https://doi.org/10.3892/etm.2021.10668